Oliver McCammon
Stock Analyst at LifeSci Capital
(4.90)
# 218
Out of 4,501 analysts
73
Total ratings
55.2%
Success rate
81.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oliver McCammon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintained: Buy | $165 | $107.58 | +53.37% | 13 | Jun 2, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | $38 | $9.68 | +292.56% | 9 | May 26, 2026 | |
| CATX Perspective Therapeutics | Maintained: Buy | $15 | $3.01 | +398.34% | 10 | May 16, 2026 | |
| CADL Candel Therapeutics | Rated: Buy | $16 | $9.49 | +68.60% | 5 | May 16, 2026 | |
| AURA Aura Biosciences | Maintained: Buy | $23 | $6.84 | +236.26% | 8 | May 16, 2026 | |
| INBX Inhibrx Biosciences | Maintained: Buy | $230 | $93.01 | +147.29% | 3 | May 16, 2026 | |
| JANX Janux Therapeutics | Rated: Buy | $60 | $16.40 | +265.85% | 12 | May 9, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintained: Buy | n/a | $23.04 | - | 13 | May 7, 2026 |
Celcuity
Jun 2, 2026
Maintained: Buy
Price Target: $165
Current: $107.58
Upside: +53.37%
Corbus Pharmaceuticals Holdings
May 26, 2026
Maintained: Buy
Price Target: $38
Current: $9.68
Upside: +292.56%
Perspective Therapeutics
May 16, 2026
Maintained: Buy
Price Target: $15
Current: $3.01
Upside: +398.34%
Candel Therapeutics
May 16, 2026
Rated: Buy
Price Target: $16
Current: $9.49
Upside: +68.60%
Aura Biosciences
May 16, 2026
Maintained: Buy
Price Target: $23
Current: $6.84
Upside: +236.26%
Inhibrx Biosciences
May 16, 2026
Maintained: Buy
Price Target: $230
Current: $93.01
Upside: +147.29%
Janux Therapeutics
May 9, 2026
Rated: Buy
Price Target: $60
Current: $16.40
Upside: +265.85%
Monte Rosa Therapeutics
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $23.04
Upside: -